A retrospective study of the clinical and economic burden during hospitalizations among cancer patients with febrile neutropenia

References

• Lyman GH, Kuderer N, Greene J, et al. The economics of febrile neutropenia: implications for the use of colony-stimulating factors. Eur J Cancer 1998;34:1857-64
   PubMed Web of Science ®Google Scholar
• Weycker D, Malin J, Edelsberg J, et al. Cost of neutropenic complications of chemotherapy. Ann Oncol 2008;19:454-60
   PubMed Web of Science ®Google Scholar
• Kuderer NM, Dale DC, Crawford J, et al. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006;106:2258-66
   PubMed Web of Science ®Google Scholar
• Kozma CM, Dickson M, Chia V, et al. Trends in neutropenia-related inpatient events. J Oncol Pract 2012;8:149-55
   PubMedGoogle Scholar
• Caggiano V, Weiss RV, Rickert TS, et al. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer 2005;103:1916-24
   PubMed Web of Science ®Google Scholar
• Schilling MB, Parks C, Deeter RG. Costs and outcomes associated with hospitalized cancer patients with neutropenic complications: a retrospective study. Exp Ther Med 2011;2:859-66
   PubMed Web of Science ®Google Scholar
• de Naurois J, Novitzky-Basso I, Gill MJ, et al. Management of febrile neutropenia: ESMO Clinical Practice Guidelines. Ann Oncol 2010;21(5 Suppl):v252-6
   Google Scholar
• Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis 2011;52:e56-93
   PubMed Web of Science ®Google Scholar
• Klastersky J, Awada A, Paesmans M, et al. Febrile neutropenia: a critical review of the initial management. Crit Rev Oncol Hematol 2011;78:185-94
   PubMed Web of Science ®Google Scholar
• Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34:730-51
   PubMed Web of Science ®Google Scholar
• American Hospital Association. 2007 AHA Hospital Statistics. Chicago, IL: Health Forum, LLC. 2006.
   Google Scholar
• Ernst FR, Davis TE, Ryan AC, et al. Linkage of a multi-hospital database to health plan claims data for continuum of care outcomes research [Abstract and Poster]. Orlando, FL: International Society for Pharmacoeconomics and Outcomes Research (ISPOR), 2009
   Google Scholar
• Michels SL, Barron RL, Reynolds MW, et al. Costs associated with febrile neutropenia in the US. Pharmacoeconomics 2012;30:809-23
   PubMed Web of Science ®Google Scholar
• Prevention and treatment of cancer-related infections, v1.2012. NCCN Clinical Practice Guidelines in Oncology, 2012. Available at: http://www.nccn.org/professionals/physician_gls/pdf/infections.pdf [Last accessed 20 December 2012]
   Google Scholar
• Aapro MS, Bohlius J, Cameron DA, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 2011;47:8-32
   PubMed Web of Science ®Google Scholar
• Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000;18:3038-51
   PubMed Web of Science ®Google Scholar
• Talcott JA, Finberg R, Mayer RJ, et al. The medical course of cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation. Arch Intern Med 1988;148:2561-8
   PubMed Web of Science ®Google Scholar
• Klastersky J, Paesmans M, Georgala A, et al. Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications. J Clin Oncol 2006;24:4129-34
   PubMed Web of Science ®Google Scholar
• Talcott JA, Siegel RD, Finberg R, et al. Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol 1992;10:316-22
   PubMed Web of Science ®Google Scholar
• Talcott JA, Yeap BY, Clark JA, et al. Safety of early discharge for low-risk patients with febrile neutropenia: a multicenter randomized controlled trial. J Clin Oncol 2011;29:3977-83
   PubMed Web of Science ®Google Scholar
• Stokes ME, Muehlenbein CE, Marciniak MD, et al. Neutropenia-related costs in patients treated with first-line chemotherapy for advanced non-small cell lung cancer. J Manag Care Pharm 2009;15:669-82
   PubMed Web of Science ®Google Scholar
• Weycker D, Edelsberg J, Kartashov A, et al. Risk and healthcare costs of chemotherapy-induced neutropenic complications in women with metastatic breast cancer. Chemotherapy 2012;58:8-18
   PubMed Web of Science ®Google Scholar
• Weycker D, Barron R, Kartashov A, et al. Incidence, treatment, and consequences of chemotherapy-induced febrile neutropenia in inpatient and outpatient settings [Abstract and Poster]. Atlanta, GA: American Society of Hematology Annual Meeting, 2012
   Google Scholar
• Bennett CL, Calhoun EA. Evaluating the total costs of chemotherapy-induced febrile neutropenia: results from a pilot study with community oncology cancer patients. Oncologist 2007;12:478-83
   PubMed Web of Science ®Google Scholar
• Cosler LE, Calhoun EA, Agboola O, et al. Effects of indirect and additional direct costs on the risk threshold for prophylaxis with colony-stimulating factors in patients at risk for severe neutropenia from cancer chemotherapy. Pharmacotherapy 2004;24:488-94
   PubMed Web of Science ®Google Scholar
• Hendricks AM, Loggers ET, Talcott JA. Costs of home versus inpatient treatment for fever and neutropenia: analysis of a multicenter randomized trial. J Clin Oncol 2011;29:3984-9
   PubMed Web of Science ®Google Scholar
• Lyman GH, Lyman CG, Sanderson RA, et al. Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy. J Natl Cancer Inst 1993;85:488-93
   PubMed Web of Science ®Google Scholar
• Cosler LE, Sivasubramaniam V, Agboola O, et al. Effect of outpatient treatment of febrile neutropenia on the risk threshold for the use of CSF in patients with cancer treated with chemotherapy. Value Health 2005;8:47-52
   PubMed Web of Science ®Google Scholar
• Myeloid growth factors, v1.2012. NCCN Clinical Practice Guidelines in Oncology, 2012. Available at: http://www.nccn.org/professionals/physician_gls/pdf/myeloid_growth.pdf [Last accessed 20 December 2012]
   Google Scholar
• Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24:3187-205
   PubMed Web of Science ®Google Scholar
• Chen-Hardee S, Chrischilles EA, Voelker MD, et al. Population-based assessment of hospitalizations for neutropenia from chemotherapy in older adults with non-Hodgkin's lymphoma (United States). Cancer Causes Control 2006;17:647-54
   PubMed Web of Science ®Google Scholar
• Weycker D, Sofrygin O, Seefeld K, et al. Technical evaluation of methods for identifying chemotherapy-induced febrile neutropenia in healthcare claims databases. BMC Health Serv Res 2013;13:60
   PubMed Web of Science ®Google Scholar